Actively Recruiting
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Led by RenJi Hospital · Updated on 2026-05-13
55
Participants Needed
1
Research Sites
291 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
CONDITIONS
Official Title
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 6518 years
- Histologically confirmed hormone receptor positive and HER2 negative breast cancer
- At least one evaluable lesion
- ECOG performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Metastatic disease (Stage IV)
- Female patients who are pregnant or lactating
- Women of childbearing potential who test positive on baseline pregnancy test
- Women of childbearing age unwilling to use effective contraception during the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here